Diarrhoea News and Research

RSS

Early promise for cannabis extract treatment in epilepsy

A preliminary, open-label study suggests that cannabidiol may be a useful adjunctive treatment in adults and children with intractable epilepsy.

7 Jan 2016

Stem cell therapy not significantly better than conventional treatment for Crohn's disease

A clinical trial to test the effectiveness of a stem cell therapy among adults with difficult to treat Crohn's disease has found it is not significantly better than conventional treatment in producing sustained disease remission after one year.

18 Dec 2015

Post-progression afatinib exposure boosts NSCLC outcomes

Continued exposure to afatinib plus paclitaxel can benefit non-small-cell lung cancer patients who developed resistance to erlotinib or gefitinib and progressed after initially responding to afatinib monotherapy, suggest phase III trial results.

11 Dec 2015

Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

The combination of ibrutinib and rituximab shows activity in patients with relapsed or refractory mantle cell lymphoma, suggests research published in The Lancet Oncology.

2 Dec 2015

Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Four-year results for an ongoing study of second-line bosutinib indicate that the tyrosine kinase inhibitor offers long-term efficacy with manageable side effects for patients with chronic phase chronic myeloid leukaemia.

27 Nov 2015

Pre-travel advice may not reduce risk of illnesses during travel

Travelling abroad involves risk of illnesses and carriage of antibiotic resistant bacteria, especially among students. Illnesses such as travellers' diarrhoea and respiratory tract infections are most common. Even if travellers follow the travel medicine clinics' advice on how to reduce risks during travel, the risk of falling ill is not reduced.

25 Nov 2015

NICE recommends Xofigo (radium-223 dichloride) for patients with advanced prostate cancer

The National Institute for Health and Care Excellence today issued its Final Appraisal Determination (FAD) recommending Xofigo (radium-223 dichloride) for use on the NHS in England as an option for treating adult men, with hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, who have received previous docetaxel therapy.

20 Nov 2015

WHO: Strong actions needed to address climate change to protect people's health

According to WHO estimates, climate change is already causing tens of thousands of deaths every year - from shifting patterns of disease, from extreme weather events, such as heat-waves and floods, and from the degradation of air quality, food and water supplies, and sanitation.

18 Nov 2015

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

17 Nov 2015

Measles vaccination plays key role in reducing child mortality

The number of measles-related deaths has decreased 79% from 546 800 at the beginning of the century to 114 900 in 2014. New data released by WHO for the Measles & Rubella Initiative, estimates that 17.1 million lives have been saved since 2000, largely due to increased vaccination coverage against this highly contagious viral disease.

13 Nov 2015

Researchers examine effectiveness of interventions to improve quality of drinking water for preventing diarrhoea

Researchers from Emory University, the London School of Hygiene and Tropical Medicine, and the World Health Organization have carried out an updated Cochrane review to assess the effectiveness of interventions to improve water quality for preventing diarrhoea.

22 Oct 2015

SMC approves Bayer's Xofigo for treatment of castration-resistant prostate cancer in NHS Scotland

The Scottish Medicines Consortium has today announced that Xofigo has been accepted for use within NHS Scotland for the treatment of adult patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

13 Oct 2015

New capsule form of FMT raises hopes for treating C. difficile infection

A new capsule form of faecal microbiota transplantation (FMT) has raised hopes that this effective treatment for Clostridium difficile (C. difficile) infection and other bowel conditions might soon become mainstream. A recently-reported study confirmed that capsules containing a frozen suspension of faecal material harvested from healthy unrelated donors was well tolerated and effectively resolved diarrhoea in 90% of patients with difficult-to-treat C. difficile infection.

7 Oct 2015

WHO and UNAIDS develop new standards to help countries improve quality of adolescent care

New Global Standards for quality health-care services for adolescents developed by WHO and UNAIDS aim to help countries improve the quality of adolescent health care.

6 Oct 2015

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, further data to support the efficacy of VARGATEF® (nintedanib*) in combination with docetaxel for the treatment of advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology

29 Sep 2015

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung

29 Sep 2015

Two-drug combination improves progression-free survival in patients with advanced melanoma

Patients with advanced melanoma skin cancer survive for longer without their disease progressing if they have been treated with a combination of two drugs, nivolumab and ipilimumab, than with either of these drugs alone. New results show that these patients also do better regardless of their age, stage of disease and whether or not they have a cancer-driving mutation in the BRAF gene.

28 Sep 2015

Combination of two targeted therapies increases survival in advanced melanoma

Latest results from a trial of a combination of two targeted therapies (dabrafenib and trametinib) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients treated with another drug, vemurafenib, when used alone.

28 Sep 2015

Patients with advanced kidney cancer benefit from cabozantinib treatment

Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases - enzymes that function as an "on" or "off" switch in many cellular processes, including cancer.

26 Sep 2015

Women’s life expectancy in eastern and western Germany continues to increase, shows study

Twenty-five years after reunification, the once considerable differences between life expectancy in eastern and western Germany have almost disappeared for women.

23 Sep 2015